Daniel Munoz
Overview
Explore the profile of Daniel Munoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
4218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Vega K, Sanllorente A, Zomeno M, Quindos A, Munoz-Martinez J, Malcampo M, et al.
Nutrients
. 2024 Aug;
16(15).
PMID: 39125261
The Mediterranean diet, featuring sourdough bread, shows promise in managing metabolic syndrome. This study explored the effects of two sourdough breads, with differing fermentation times but similar nutritional profiles, on...
2.
Marquis-Gravel G, Mulder H, Wruck L, Benziger C, Effron M, Farrehi P, et al.
BMJ Open
. 2024 Aug;
14(8):e078197.
PMID: 39117415
Objectives: To evaluate whether the effectiveness and safety of low (81 mg daily) versus high-dose (325 mg daily) aspirin is consistent across races among patients with established atherosclerotic cardiovascular disease...
3.
Rymer J, Mulder H, Wruck L, Munoz D, Kripalani S, Effron M, et al.
JAMA Cardiol
. 2024 Jul;
9(9):852-857.
PMID: 39046724
Importance: Pragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied. Objective: To...
4.
Benziger C, Stebbins A, Wruck L, Effron M, Marquis-Gravel G, Farrehi P, et al.
JAMA Cardiol
. 2024 Jul;
9(9):808-816.
PMID: 38985488
Importance: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in...
5.
Munoz D, Cano C, Amador J, Vergara S, Ruiz G
Rev Med Chil
. 2024 Apr;
151(5):541-550.
PMID: 38687535
Background: The largest growth in cases of COVID-19 worldwide during 2020 was in the Americas, and Chile was one of the most affected countries. Aim: To describe, characterize, and evaluate...
6.
Ward M, Kripalani S, Munoz D, Collins S, Moser K, Jenkins C, et al.
Am J Accountable Care
. 2024 Apr;
10(3):7-15.
PMID: 38617098
Objectives: Interfacility transfer for time-sensitive emergencies involves rapid and complex care transitions between facilities. We sought to validate relational coordination, a 7-dimension measure of coordination in which a higher score...
7.
Munoz A, Munoz D, Cardozo A
J Vasc Surg Venous Lymphat Disord
. 2024 Jan;
12(4):101728.
PMID: 38244858
No abstract available.
8.
Soto C, Salinas P, Munoz D, Olivares S, Gonzalez J, Saez V, et al.
J Med Life
. 2023 Oct;
16(7):1017-1021.
PMID: 37900065
In this retrospective study, we aimed to evaluate the effects of the neurotrophic compound Cerebrolysin on executive, cognitive, and functional performance in patients with traumatic brain injury (TBI) with a...
9.
Girotra S, Stebbins A, Wruck L, Marquis-Gravel G, Gupta K, Farrehi P, et al.
J Am Heart Assoc
. 2023 Oct;
12(20):e030385.
PMID: 37830344
Background The ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high- versus low-dose aspirin for...
10.
Sleem A, Effron M, Stebbins A, Wruck L, Marquis-Gravel G, Munoz D, et al.
JAMA Cardiol
. 2023 Oct;
8(11):1061-1069.
PMID: 37792369
Importance: Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations....